ALX Oncology raises $105 million in Series C financing for CD47 trials

By Akshay Kedari  Date: 2020-02-14

ALX Oncology raises $105 million in Series C financing for CD47 trials

ALX Oncology, a clinical-stage biotechnology company, has secured $105 million in a Series C funding round, led by Vivo Capital. The new investors, who participated in the funding round include Janus Henderson, Logos Capital, Foresite Capital, BVF Partners, HBM Healthcare Investments, and Cormorant Asset Management. The Series C funding round also witnessed the participation of existing investors Lightstone Ventures and Existing investors venBio, who had participated in the previous two rounds.

The latest funds will be used to further phase 2 study of CD47 myeloid checkpoint inhibitor ALX148 along with other anti-cancer treatments. The Series C funding round comes after the revelation of data by ALX on patients suffering from relapsed or refractory non-Hodgkin lymphoma (NHL), who have been treated using ALX148 in combination with rituximab. Among the 21 evaluable subjects, the company observed a median progression-free survival of 7.3 months and an objective response rate of around 43%. The drug was noted to be well tolerated and relatively safe.

Corey Goodman, Co-Founder and Executive Chairman, ALX, reportedly stated that from the initial days, the company believed that it will be the best-in-class in the CD47 checkpoint pathway by utilizing a ‘dead’ Fc domain that does not bind to macrophages, thus lessening the cytopenias and other toxicities related to this class of agents. The company is elated to observe the clinical results supporting its hypothesis and offering the opportunity for higher dosing and increased efficacy, he further added.

The phase 1 study, that generated the lymphoma data is progressing with other arms of the trial testing the potential of CD47 in combination with Keytruda and Herceptin in patients suffering from a solid tumor. But, with ALX148 coming through its first trial in NHL, ALX intends to take the candidate deeper into the clinic. The series C financing proceeds will be used to bankroll the further development of ALX148. 
 

Source links:

https://www.fiercebiotech.com/biotech/alx-raises-105m-for-midphase-trials-cd47-cancer-drug

 

About Author

Akshay Kedari     aeresearch.net

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Tesla gets German nod to develop test cars at unfinished Berlin factory

Tesla gets German nod to develop test cars at unfinished Berlin factory

By Akshay Kedari

Tesla Inc. has reportedly received authorization to produce test cars at its unfinished German gigafactory. This approval comes as the EV maker continues to wait for the project's final permission, although Tesla will not be permitted to sell the...

Power Gummies secures USD 6 million in 9Unicorns-led Series A funding

Power Gummies secures USD 6 million in 9Unicorns-led Series A funding

By Akshay Kedari

Nutraceutical startup Power Gummies has reportedly raised USD 6 million during a Series A funding which was led by 9Unicorns. The round also saw participation from other investors such as NB Ventures, Sharpp Ventures (Marico Family Office), Wipr...

Marriot establishes a research & development lab to promote innovation

Marriot establishes a research & development lab to promote innovation

By Akshay Kedari

Hospitality behemoth Marriott International Inc. has reportedly established a research and development lab called the “Design Lab” to strengthen and optimize the rollout of its current product offerings. This lab will encompass all areas...

Sony to steer into the electric vehicle space with a new mobility unit

Sony to steer into the electric vehicle space with a new mobility unit

By Akshay Kedari

Sony will establish a subsidiary, ‘Sony Mobility Inc.’ that will primarily focus on its EV business. The company unveiled a new electric SUV prototype, called the Vision-S 02 at CES 2022. Sony Group Corporation, a Japanese electroni...

Apple becomes world's first company to reach USD 3 trillion valuation

Apple becomes world's first company to reach USD 3 trillion valuation

By Akshay Kedari

Apple Inc. recently became the first company to have a stock market value of USD 3 trillion, boosted by investor confidence that the iPhone manufacturer will continue to release best-selling products while foraying into new markets such as self-drivi...